Imidazoquinoline derivatives (IMDs) and related compounds function as synthetic agonists
of Toll-like receptors 7 and 8 (TLR7/8) and one is FDA approved for topical antiviral and skin …

SUMMARY Herpes simplex virus 1 (HSV-1) is very successful in establishing acute and
latent infections in humans by counteracting host antiviral innate immune responses. HSV-1 …

Imiquimod is an immune response modifier commercially available as a 3.75 and 5% cream.
Topical imiquimod stimulates the innate and adaptive immune responses and induces …

The immune response modifiers, imiquimod and resiquimod, are TLR7 agonists that induce
type I interferon in numerous species, including humans. Recently, it was shown that …

Herpes simplex viruses type 1 (HSV-1) and type 2 (HSV-2) have co-evolved with humans for
thousands of years and are present at a high prevalence in the population worldwide. HSV …

Imiquimod, an imidazoquinoline amine, is an immune response modifier recently approved
for the topical treatment of external genital and perianal warts. Although the majority of …

Immunotherapies that can either activate or suppress innate immune responses are being
investigated as treatments against infectious diseases and the pathology they can cause …

1 H-Imidazo-[4, 5-c] quinolines were prepared while investigating novel nucleoside
analogues as potential antiviral agents. While these compounds showed no direct antiviral …

Imiquimod 5% cream is approved for the topical treatment of external anogenital warts
caused by human papillomavirus (HPV) and for the skin cancer conditions superficial basal …

Introduction: Resiquimod is an immune response modifier which stimulates cells through a
toll-like receptors (TLR) 7 and 8 dependent pathway resulting in activation of immune …